Study drug for advanced liver cancer that cannot be removed
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests TTI-101, by itself and with other cancer medicines, for liver cancer that is advanced and cannot be removed by surgery. It aims to see whether the treatment can slow the cancer down and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to understand and sign consent.
- You must have confirmed advanced or metastatic liver cancer that cannot be surgically removed (HCC).
- Your cancer must have measurable signs on scans, and you must have an active plan that matches the trial’s prior-treatment rules.
- You must be able to swallow pills and be in fairly good physical condition (ECOG 0–1).
- Your blood tests and organ functions (liver, kidneys, blood counts) must meet minimum levels.
- If you can become pregnant or have a partner who can become pregnant, you must use effective birth control during the study and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests whether giving a combination of two immunotherapy drugs before a liver transplant can help people with advanced liver cancer (beyond standard size limits) receive a transplant successfully. The treatment aims to shrink the tumor and improve outcomes.
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial combines three medications—an immunotherapy (atezolizumab), a drug that blocks blood vessel growth (bevacizumab), and one that reduces inflammation (tocilizumab)—to see if they work together against advanced liver cancer. The goal is to slow cancer growth and possibly shrink the tumor.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.